Want to see GB:PRM full AI Analyst Report?
Top Page
Proteome Sciences
(LSE:PRM)
Select Model
Select Model
Rating:41Neutral
Price Target:
1.50 p
▼(-5.06% Downside)
Action:Reiterated
Date:10/09/26
The score is driven primarily by weak financial performance, especially deteriorating profitability and a strained balance sheet with rising debt and negative equity. Technical indicators add to risk with a clear downtrend (price below major moving averages and negative MACD). Valuation is not supportive because the company is loss-making and no dividend yield is provided.
Positive Factors
Proteomics service model
The fee-for-service model addresses ongoing analytical needs in drug discovery and biomarker research across pharma, biotech, and academic customers. This established service capability can support repeat project demand and revenue diversification if laboratory utilization and customer retention improve.
Negative Factors
Revenue and profitability deterioration
Falling revenue combined with negative gross profit and persistent operating and net losses shows weak cost absorption and limited earnings stability. Continued deterioration could constrain investment in proteomics capabilities and make the business more dependent on financing or strategic support.
Read all positive and negative factors
Positive Factors
Negative Factors
Proteomics service model
The fee-for-service model addresses ongoing analytical needs in drug discovery and biomarker research across pharma, biotech, and academic customers. This established service capability can support repeat project demand and revenue diversification if laboratory utilization and customer retention improve.
Read all positive factors
Proteome Sciences (PRM) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£4.98M
Dividend YieldN/A
Average Volume (3M)202.49K
Price to Earnings (P/E)―
Beta (1Y)0.22
Revenue Growth-16.72%
EPS Growth36.28%
CountryUK
Employees32
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding350,724,900
10 Day Avg. Volume36,841
30 Day Avg. Volume202,492
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)-0.77
Price to Sales (P/S)1.96
P/FCF Ratio-51.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Proteome Sciences Business Overview & Revenue Model
Company Description
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a sta...
How the Company Makes Money
Proteome Sciences primarily makes money by providing fee-for-service proteomics and analytical R&D services to external customers. The core revenue stream is contract revenue from studies where clients pay for experimental design support and execu...
Proteome Sciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
26
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.77M | 3.76M | 4.89M | 5.03M | 7.78M | 5.12M |
| Gross Profit | -956.00K | -1.01M | -167.00K | 1.16M | 4.77M | 2.96M |
| EBITDA | -1.30M | -1.74M | -1.52M | -1.14M | 2.01M | 625.00K |
| Net Income | -2.32M | -3.06M | -3.41M | -2.44M | 1.32M | 72.00K |
Balance Sheet | ||||||
| Total Assets | 7.67M | 8.26M | 9.21M | 11.46M | 12.43M | 10.04M |
| Cash, Cash Equivalents and Short-Term Investments | 1.10M | 781.00K | 1.13M | 2.03M | 3.99M | 2.39M |
| Total Debt | 15.95M | 15.77M | 14.52M | 13.47M | 11.91M | 11.69M |
| Total Liabilities | 17.57M | 17.79M | 15.72M | 14.52M | 13.28M | 12.82M |
| Stockholders Equity | -9.90M | -9.53M | -6.52M | -3.07M | -843.00K | -2.77M |
Cash Flow | ||||||
| Free Cash Flow | 367.00K | -143.00K | -1.05M | -718.00K | 2.14B | 8.80B |
| Operating Cash Flow | 425.00K | -46.00K | -826.00K | -481.00K | 3.88B | 10.52B |
| Investing Cash Flow | -56.00K | -97.00K | -224.00K | -424.00K | -21.67B | 4.27B |
| Financing Cash Flow | 461.00K | -204.00K | 151.00K | -1.06M | -209.00K | -400.00K |
Proteome Sciences Technical Analysis
Negative
1.58
Price Trends
1.56
Negative
1.62
Negative
1.79
Negative
Market Momentum
-0.03
Negative
39.59
Neutral
43.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRM, the sentiment is Negative. The current price of 1.58 is above the 20-day moving average (MA) of 1.43, above the 50-day MA of 1.56, and below the 200-day MA of 1.79, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 39.59 is Neutral, neither overbought nor oversold. The STOCH value of 43.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:PRM.
Proteome Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £18.46M | -1.06 | -1044.57% | ― | 65.60% | 74.84% | |
48 Neutral | £9.66M | -0.49 | -104.73% | ― | -56.10% | 41.10% | |
47 Neutral | £6.09M | -1.42 | -77.85% | ― | 11.90% | -2864.29% | |
44 Neutral | £5.15M | -0.58 | -127.57% | ― | 77.87% | 84.36% | |
41 Neutral | £4.98M | -1.86 | 23.85% | ― | -16.72% | 36.28% | |
40 Underperform | £4.71M | -0.47 | -481.34% | ― | -10.81% | 42.67% |
* Healthcare Sector Average
GB:PRM
Proteome Sciences
1.36
-0.47
-25.55%
GB:CLBX
ANGLE plc
0.85
-1.35
-61.36%
GB:GDR
Genedrive
1.15
0.80
228.57%
GB:OPTI
OptiBiotix Health
5.90
-4.35
-42.44%
GB:VRCI
Verici Dx Plc
0.23
-0.40
-64.00%
GB:GENI
GENinCode UK Ltd.
0.63
-2.98
-82.64%
Proteome Sciences Corporate Events
Business Operations and StrategyExecutive/Board Changes
Proteome Sciences Adds Former KPMG International CFO Helen Spice to Board
Positive
Sep 16, 2026
Proteome Sciences plc has strengthened its board with the appointment of Helen Spice as an independent non-executive director, effective immediately. Spice, a former CFO of KPMG International and current non-executive director at Barts Health NHS ...
Business Operations and StrategyFinancial Disclosures
Proteome Sciences Builds Order Book as Targeted Proteomics Demand and TMT Sales Rise
Positive
Sep 16, 2026
Proteome Sciences reported interim revenues of £1.87m for the first half of 2026, broadly flat year-on-year, with lower services income offset by stronger TMT reagent sales and royalties, and an improved gross profit thanks to reduced costs. ...
Business Operations and Strategy
Proteome Sciences Wins Major GCLP Chemoproteomics Contract for Global Clinical Trials
Positive
Sep 15, 2026
Proteome Sciences has secured a significant new clinical chemoproteomics contract that will be conducted under Good Clinical Laboratory Practice at its Frankfurt laboratories. The engagement, linked to the same protein studied in two earlier proje...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.